# Yarrow Bioscience, Inc. (VYNE) — delisting [announced]
Source: SEC API (secapi.ai) · situation sit_201c9935053c2da8a8d1 · retrieved 2026-08-12T06:57:42.005Z

## Overview
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc. and Menlo Therapeutics Inc.) is a pharmaceutical company engaged in pharmaceutical preparations.

On July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc., with Yarrow continuing as a wholly owned subsidiary of VYNE under the name "Yarrow Bioscience Operating Company Corp." In connection with the merger, OrbiMed Private Investments X, LP received 233,019 shares and pre-funded warrants to purchase 4,084,827 shares, and OrbiMed Genesis Master Fund, L.P. received 33,287 shares and warrants to purchase 583,545 shares. The warrants contain an exercise limitation (the "Blocker") that prohibits the holder from exercising warrants to the extent that after exercise the holder would beneficially own in excess of 9.99% of outstanding shares, and the exercise price is $0.0001 per share.

## Terms
- Counterparty: VYNE Therapeutics Inc. · Consideration: stock · Stake: 9.97% · Price/share: $0.0001

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · SCHEDULE 13D (0000947871-26-000747): SCHEDULE 13D - Yarrow Bioscience, Inc. — *Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc. and Menlo Therapeutics Inc.) is a pharmaceutical company engaged in pharmaceutical preparations.* On July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc., with Yarrow continuing as a wholly owned subsidiary of VYNE under the name "Yarrow Bioscience Operating Company Corp." In connection with the merger, OrbiMed Private Investments X, LP received 233,019 shares and pre-funded warrants to purchase 4,084,827 shares, and OrbiMed Genesis Master Fund, L.P. received 33,287 shares and warrants to purchase 583,545 shares. The warrants contain an exercise limitation (the "Blocker") that prohibits the holder from exercising warrants to the extent that after exercise the holder would beneficially own in excess of 9.99% of outstanding shares, and the exercise price is $0.0001 per share.
  https://www.sec.gov/Archives/edgar/data/1566044/0000947871-26-000747.txt

## Citations
- 0000947871-26-000747 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000094787126000747